Cyntellect this week said it has appointed three new members to its scientific advisory board: Alan Aderem, director of the Institute for Systems Biology and former head of the signal transduction laboratory at Rockefeller University; Charles Cantor, chief scientific officer at Sequenom and former chair and professor of biomedical engineering at Boston University; and Michael Hanley, vice president of discovery research at Amylin Pharmaceuticals and former senior faculty at Imperial College, London.
Tony White, Cathy Burzik, James Noble, Alan Aderem, Michael Hanley
Tony White will remain interim president of Applied Biosystems for one or two more years, White said during a conference call with investors and analysts last week. White, CEO of ABI’s parent company Applera, succeeded Cathy Burzik last October, when she stepped down as president of ABI. “As of now, the board of directors and I have no plans to conduct an external search,” White said in last week’s call. “Rather, we are focusing on further developing the high potential leadership team within Applied Biosystems,” he said.
CuraGen, parent company of 454 Life Sciences, has appointed James Noble to its board of directors. He will serve as a member of the board’s nominating and governance committee and the audit committee. Noble also serves on the board of GW Pharmaceuticals and the supervisory board of MediGene and is non-executive director of Bionex Investments and of Finsbury Worldwide Pharmaceutical Trust. Prior to that, he was CEO of Avidex.
Noble has also served as a non-executive director of Powderject Pharmaceuticals, Oxford Glycosciences, Advanced Medical Solutions, Oxagen, Adprotech Pharmaceuticals, Anthra Pharmaceuticals, PAA, Prolifix, and Neurovex. From 1990 to 1997, Noble was CFO of British Biotech. Prior to that, he was director at Kleinwert Benson.